Pursuant to Regulation 30, 33 and schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board of Directors of the Company at its meeting held today, ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The Board of Directors of Wardwizard Healthcare Ltd approved the unaudited standalone financial results for Q2 and H1 FY26 (ended September 30, 2025). Revenue from operations grew to roughly Rs. 26.16 lakhs in H1 FY26 vs Rs. 19.00 lakhs in H1 FY24, but the company continued to report losses at Rs. (25.95) lakhs for the half year and Rs. (10.62) lakhs for Q2. Total equity stood at a very thin Rs. 16.76 lakhs, indicating a weak balance sheet. The Board also appointed Mr. Yuvraj Priyadarshi as the new CEO and reconstituted the Stakeholders Relationship Committee. Critically, the statutory auditor M/s. Mahesh Udhwani & Associates issued a Limited Review Report containing an Emphasis of Matter, flagging that the company's business operations were 'temporarily suspended geographically' and that 'Management is reviewing the feasibility of future operations.'
This is a significant red flag for shareholders. The auditor's explicit reference to suspended business operations and the management reviewing the 'feasibility of future operations' raises serious going-concern doubts about the company's ability to continue as a going concern, which could weigh heavily on the stock price and investor confidence despite the modest revenue uptick.